| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6930119 | BRAINTREE | Liquid pharmaceutical composition |
Jul, 2022
(1 year, 9 months ago) | |
Axid is owned by Braintree.
Axid contains Nizatidine.
Axid has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Axid are:
- US6930119
Axid was authorised for market use on 25 May, 2004.
Axid is available in solution;oral dosage forms.
The generics of Axid are possible to be released after 17 July, 2022.
Drugs and Companies using NIZATIDINE ingredient
Market Authorisation Date: 25 May, 2004
Treatment: NA
Dosage: SOLUTION;ORAL
How can I launch a generic of AXID before it's drug patent expiration?
More Information on Dosage
AXID family patents
